A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with AK117 versus pembrolizumab combined with placebo in patients with R/M HNSCC whose tumors have programmed cell death-ligand 1 (PD-L1) positive \[Combined Positive Score (CPS) greater than or equal to 1\].
Head and Neck Squamous Cell Carcinoma
DRUG: AK117 in combination with AK112|DRUG: Placebo in combination with Pembrolizumab
Overall Survival (OS), OS is the time from randomization to death due to any cause., Up to approximately 2 years
Progression Free Survival (PFS), PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first., Up to approximately 2 years|Objective Response Rate (ORR), ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1., Up to approximately 2 years|Adverse Events (AEs), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment., Up to approximately 2 years|Cmax, Maximum plasma concentration of AK112 and AK117 after administration., Up to approximately 2 years|Cmin, Minimum plasma concentration of AK112 and AK117 after administration., Up to approximately 2 years|Anti-drug antibodies (ADA), Number of subjects with detectable ADA., Up to approximately 2 years
This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with AK117 versus pembrolizumab combined with placebo in patients with R/M HNSCC whose tumors have programmed cell death-ligand 1 (PD-L1) positive \[Combined Positive Score (CPS) greater than or equal to 1\].